Why microdosing is gaining momentum in Australia
Australian Financial Review, March 24, 2022
Microdosing psychedelic drugs has been a trend in Silicon Valley that’s taking off here. But does a micro trip help you make better decisions at work?
LSD, a future anti-anxiety pill?
McGill University Health Centre, March 18, 2022
A study conducted by Gabriella Gobbi, MD, Professor and Head of the Neurobiological Psychiatry Unit in the Department of Psychiatry, and her team demonstrates for the first time that regular administration of low doses of LSD (lysergic acid diethylamide) reduces anxiety symptoms through neurobiological mechanisms that are similar to those of selective serotonin reuptake inhibitors (SSRIs).
Psychedelics and the Future of Psychiatry
The Psychiatric Times, February 9, 2022
Over the past several years, we have witnessed a psychedelic renaissance, and a growing body of evidence suggests that several psychedelic compounds hold strong therapeutic potential for a wide array of mental health conditions.
Psychedelics Offer New Route to Recovery from Eating Disorders
Neo Life, February 1, 2022
Psilocybin, MDMA, and ketamine can lead to a new sense of self and a release from rigid rules for people with anorexia, bulimia, and binge-eating disorder.
Sensible policy on psychedelic drugs is growing more common
The Economist, January 29, 2022
Psychedelic drugs show tremendous potential in treating certain mental health disorders.
Psychedelic therapy shows great promise. More states should legalise it
The Economist, January 29, 2022
Oregon’s trailblazing sets a fine example.
The Future of Psychedelic Medicine Will Be Drugs You’ve Never Heard Of
Vice, January 25, 2022
Scientists are designing new psychedelic-inspired drugs that don’t yet exist, which might have effects no one can yet describe.
Ketamine for the treatment of alcoholism
Blossom Analysis, January 24, 2022
Psychedelics are poised to be both viable and effective treatment options for many people living with mental disorders whom conventional treatments have failed. One of these disorders is substance use disorder (SUD), commonly known as addiction.
How 2021 became the year of psychedelics – and why 2022 is set to be even bigger
Canex, January 20, 2022
It’s no secret that psychedelics are on the comeback trail, with a record number of trials and total investment in the hundreds of millions of dollars in 2021 alone.
How magic mushrooms changed my life
Financial Review, January 19, 2022
So, can psilocybin really help those with depression? I was skeptical, but the retreat changed my mind.
Health Canada’s New SAP Rules: A Q&A With Numinus’ Payton Nyquvest
Psychedelic Stock Watch, January 10, 2022
In 2020, Health Canada began tentative steps to open up legal access to psychedelics-based therapies via “exemptions” granted through its Special Access Program (SAP).
Therapists hail ‘legalization’ of medicinal psychedelic drugs
Calgary Herald, January 7, 2022
Local therapists say Ottawa’s move allowing physicians to prescribe psychedelics is a “seismic shift” towards legalizing their medicinal use.
$14.8 million for innovative mental health clinical trials
Health.gov.au, January 7, 2022
Seven clinical trials testing the use of potential breakthrough combination therapies to treat debilitating mental illnesses will receive a total of almost $15 million from the Australian Government’s Medical Research Future Fund (MRFF).
Canada Opens New Legal Pathways For Access To Psychedelics Treatment With Psilocybin And MDMA
Benzinga, January 5, 2022
In a groundbreaking decision, the Canadian government is changing the way patients can access psychedelic therapies with restricted drugs, including MDMA and psilocybin.
Depression and Grief Wrecked a Man’s Life—Until He Took Magic Mushroom Ingredient
Newsweek, December 26, 2021
Five years after taking part in a clinical trial, Kirk Rutter, spoke to Newsweek about his experiences of the trial and its impact on his mental health.
Exclusive: Three Canadians with mental health conditions receive legal access to psilocybin mushrooms
The Growth Op, December 13, 2021
Three Canadians struggling with mental health conditions have received exemptions to the Controlled Drugs and Substances Act from the federal Minister of Health Jean-Yves Duclos.
Psychedelics for mental illness
ABC News, December 12, 2021
Major trials are bringing us a step closer to seeing psychedelic substances used in therapy practice for PTSD, anxiety and depression. On this episode of All in the Mind, we take a look at where the research is currently at with our Ambassadors Dr Rick Doblin and Professor David Nutt.
‘This isn’t the 60s again’: psychedelics business takes off amid culture clash
The Guardian, December 12, 2021
Experts fear if psychedelics fall exclusively into the hands of big pharma the industry will follow the same path as legal marijuana, making the rich richer.
Psychedelics can change humanity for the better. It’s time to unlock their power
The Guardian, November 26, 2021
Founder and Executive Director at MAPS and an Ambassador for Mind Medicine Australia, Dr Rick Doblin (USA) is at the heart of the psychedelic movement. In this article he shares some of his findings and progress.
Doctor takes bid to treat patient with MDMA to court, in first case of its kind in Australia
ABC News, November 12, 2021
There’s growing interest in the use of psychedelic medicine in the treatment of complex mental health disorders like depression and PTSD.